Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients.[1] As of June 2008[update], the first Phase III clinical trial has been completed.[2]
Identifiers | |
---|---|
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C28H30ClN5O3 |
Molar mass | 520.03 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(verify) |
Lecozotan is a competitive, selective 5-HT1A receptor antagonist[3] which enhances the potassium-stimulated release of acetylcholine and glutamate.[4]